Index -
P/E 618.61
EPS (ttm) 0.25
Insider Own 7.05%
Shs Outstand 55.77M
Perf Week -9.11%
Market Cap 8.72B
Forward P/E 77.72
EPS next Y 2.01
Insider Trans -1.15%
Shs Float 51.96M
Perf Month -6.27%
Income 14.84M
PEG 36.15
EPS next Q 0.33
Inst Own 101.43%
Short Float 8.38%
Perf Quarter -18.98%
Sales 607.45M
P/S 14.36
EPS this Y -16.94%
Inst Trans 1.47%
Short Ratio 9.62
Perf Half Y -3.49%
Book/sh 35.29
P/B 4.42
EPS next Y 38.21%
ROA 0.55%
Short Interest 4.35M
Perf Year -6.98%
Cash/sh 13.97
P/C 11.18
EPS next 5Y 17.11%
ROE 0.76%
52W Range 110.45 - 211.13
Perf YTD -13.16%
Dividend Est. -
P/FCF 79.65
EPS past 5Y 15.08%
ROI 0.56%
52W High -26.05%
Beta 1.05
Dividend TTM -
Quick Ratio 5.24
Sales past 5Y 31.42%
Gross Margin 42.41%
52W Low 41.36%
ATR (14) 5.59
Dividend Ex-Date -
Current Ratio 6.35
EPS Y/Y TTM -91.17%
Oper. Margin 5.52%
RSI (14) 35.85
Volatility 3.09% 3.34%
Employees 1783
Debt/Eq 0.37
Sales Y/Y TTM -21.90%
Profit Margin 2.44%
Recom 1.50
Target Price 204.80
Option/Short Yes / Yes
LT Debt/Eq 0.33
EPS Q/Q -92.68%
Payout 0.00%
Rel Volume 1.59
Prev Close 158.16
Sales Surprise -3.30%
EPS Surprise -6.98%
Sales Q/Q -17.14%
Earnings May 01 BMO
Avg Volume 452.73K
Price 156.14
SMA20 -6.24%
SMA50 -9.69%
SMA200 -8.44%
Trades
Volume 283,879
Change -1.28%
Date
Action
Analyst
Rating Change
Price Target Change
Dec-04-23 Downgrade
The Benchmark Company
Buy → Hold
Jul-20-23 Initiated
Wells Fargo
Overweight
$185
Jul-05-23 Resumed
JP Morgan
Overweight
$220
Mar-28-23 Initiated
The Benchmark Company
Buy
$230
Dec-14-22 Initiated
Deutsche Bank
Hold
$180
Dec-07-22 Initiated
RBC Capital Mkts
Sector Perform
$190
Jul-20-22 Initiated
UBS
Buy
$213
Oct-14-21 Initiated
Exane BNP Paribas
Outperform
$330
Nov-10-20 Initiated
KeyBanc Capital Markets
Overweight
$241
Aug-24-20 Reiterated
H.C. Wainwright
Buy
$151 → $168
Jun-30-20 Reiterated
H.C. Wainwright
Buy
$143 → $151
May-07-20 Reiterated
H.C. Wainwright
Buy
$100 → $143
Mar-23-20 Reiterated
H.C. Wainwright
Buy
$110 → $100
Nov-15-19 Initiated
Stifel
Buy
Nov-01-19 Upgrade
First Analysis Sec
Outperform → Strong Buy
$107 → $110
Oct-15-19 Initiated
SVB Leerink
Outperform
$100
Aug-28-19 Reiterated
First Analysis Sec
Outperform
$95 → $107
Aug-23-19 Resumed
Stephens
Overweight
Jul-22-19 Upgrade
H.C. Wainwright
Neutral → Buy
$110
Dec-17-18 Upgrade
CL King
Neutral → Buy
Show Previous Ratings
May-23-24 02:12AM
May-22-24 07:30AM
May-15-24 09:53AM
May-07-24 07:30AM
May-02-24 11:31AM
11:31AM
Loading…
11:31AM
11:23AM
03:06AM
May-01-24 11:53AM
09:11AM
08:50AM
08:47AM
07:47AM
(Associated Press Finance)
07:30AM
Apr-23-24 11:43AM
07:30AM
Loading…
Apr-17-24 07:30AM
Apr-12-24 10:07AM
09:49AM
Mar-19-24 07:30AM
Mar-12-24 01:18AM
Feb-27-24 02:02AM
Feb-24-24 12:03AM
Feb-22-24 11:24AM
10:39AM
Feb-21-24 08:45AM
08:12AM
07:51AM
(Associated Press Finance)
07:30AM
Feb-07-24 07:30AM
Jan-31-24 12:10PM
05:09AM
Loading…
Jan-29-24 05:09AM
Dec-19-23 07:30AM
Dec-18-23 04:49AM
Dec-07-23 07:30AM
Nov-30-23 11:31AM
Nov-15-23 07:15AM
Nov-14-23 02:01PM
07:30AM
Nov-07-23 07:30AM
Nov-02-23 07:30AM
Nov-01-23 12:10PM
11:46AM
12:04AM
(Thomson Reuters StreetEvents)
Oct-31-23 09:41AM
09:12AM
08:50AM
07:41AM
(Associated Press Finance)
07:30AM
Oct-25-23 10:01AM
Oct-24-23 10:00AM
Oct-17-23 11:44AM
07:30AM
Oct-02-23 07:30AM
Sep-27-23 06:51AM
Sep-26-23 12:41PM
(American City Business Journals)
07:30AM
Sep-14-23 10:10AM
Sep-12-23 07:30AM
Sep-06-23 03:06AM
Sep-01-23 12:19PM
11:31AM
07:30AM
Aug-21-23 06:53AM
Aug-17-23 08:00AM
Aug-10-23 09:39AM
Aug-09-23 06:10AM
Aug-03-23 11:19AM
Aug-02-23 08:55AM
07:49AM
07:30AM
Jul-31-23 09:08AM
Jul-26-23 10:02AM
Jul-25-23 11:40AM
Jul-20-23 10:01AM
Jul-19-23 07:30AM
Jul-10-23 08:34AM
Jun-30-23 10:54AM
Jun-21-23 08:00PM
Jun-07-23 11:30AM
Jun-02-23 11:31AM
Jun-01-23 11:31AM
May-31-23 07:30AM
May-30-23 12:09PM
May-09-23 05:52PM
May-03-23 01:20PM
May-02-23 11:36PM
(Thomson Reuters StreetEvents)
08:55AM
07:52AM
07:30AM
07:02AM
May-01-23 07:43AM
Apr-26-23 08:00PM
10:02AM
Apr-25-23 02:07PM
10:01AM
Apr-18-23 07:30AM
Apr-11-23 02:41PM
Mar-24-23 11:30AM
Mar-14-23 07:30AM
Feb-23-23 06:28PM
Repligen Corp. is a global life sciences company, which engages in providing bioprocessing technologies and solutions used in the process of manufacturing biological drugs. It operates through the North America. Europe, and Asia Pacific Region or Other geographical segments. The company was founded by Alexander G. Rich and Paul R. Schimmel in May 1981 and is headquartered in Waltham, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Hunt Anthony Chief Executive Officer May 21 '24 Sale 168.26 20,072 3,377,283 163,177 May 22 05:14 PM KURIYEL RALF Senior VP, R&D Mar 11 '24 Option Exercise 86.10 1,271 109,433 27,777 Mar 12 08:24 PM KURIYEL RALF Senior VP, R&D Mar 11 '24 Sale 193.73 3,517 681,348 24,260 Mar 12 08:24 PM Hunt Anthony Chief Executive Officer Mar 08 '24 Option Exercise 16.55 1 17 201,956 Mar 11 07:43 PM Hunt Anthony Chief Executive Officer Mar 08 '24 Sale 197.44 16,707 3,298,632 185,249 Mar 11 07:43 PM DAWES KAREN A Director Feb 27 '24 Option Exercise 42.07 4,626 194,616 88,367 Feb 28 09:56 PM DAWES KAREN A Director Feb 27 '24 Sale 193.35 1,000 193,350 87,367 Feb 28 09:56 PM Bylund James Chief Operating Officer Feb 23 '24 Option Exercise 94.33 940 88,670 18,508 Feb 26 08:38 PM Bylund James Chief Operating Officer Feb 23 '24 Sale 198.08 4,373 866,204 14,135 Feb 26 08:38 PM Gebski Christine See Remarks Nov 10 '23 Sale 147.13 3,788 557,328 28,787 Nov 13 05:10 PM DAWES KAREN A Director Aug 29 '23 Option Exercise 18.12 7,392 133,943 84,591 Aug 30 04:06 PM DAWES KAREN A Director Aug 29 '23 Sale 171.38 850 145,673 83,741 Aug 30 04:06 PM
Index RUT
P/E -
EPS (ttm) -3.35
Insider Own 4.34%
Shs Outstand 57.56M
Perf Week -4.08%
Market Cap 2.51B
Forward P/E -
EPS next Y -2.53
Insider Trans -0.91%
Shs Float 55.70M
Perf Month 36.46%
Income -192.14M
PEG -
EPS next Q -0.77
Inst Own 114.96%
Short Float 19.22%
Perf Quarter 5.00%
Sales 277.49M
P/S 9.03
EPS this Y 17.01%
Inst Trans 2.35%
Short Ratio 11.38
Perf Half Y 75.78%
Book/sh 9.63
P/B 4.47
EPS next Y 15.18%
ROA -24.68%
Short Interest 10.70M
Perf Year 187.70%
Cash/sh 5.04
P/C 8.54
EPS next 5Y -
ROE -30.40%
52W Range 14.20 - 50.50
Perf YTD 16.77%
Dividend Est. -
P/FCF -
EPS past 5Y -6.09%
ROI -30.26%
52W High -14.77%
Beta 1.79
Dividend TTM -
Quick Ratio 5.06
Sales past 5Y 60.13%
Gross Margin 38.29%
52W Low 203.10%
ATR (14) 2.28
Dividend Ex-Date -
Current Ratio 5.51
EPS Y/Y TTM 11.09%
Oper. Margin -68.89%
RSI (14) 56.48
Volatility 4.47% 6.11%
Employees 919
Debt/Eq 0.16
Sales Y/Y TTM 21.79%
Profit Margin -69.24%
Recom 1.80
Target Price 43.38
Option/Short Yes / Yes
LT Debt/Eq 0.13
EPS Q/Q 24.44%
Payout -
Rel Volume 0.67
Prev Close 42.23
Sales Surprise 6.51%
EPS Surprise 3.15%
Sales Q/Q 25.13%
Earnings May 02 AMC
Avg Volume 940.36K
Price 43.04
SMA20 2.94%
SMA50 19.25%
SMA200 46.39%
Trades
Volume 248,768
Change 1.92%
Date
Action
Analyst
Rating Change
Price Target Change
Jan-17-24 Upgrade
Goldman
Neutral → Buy
$25 → $45
Sep-27-23 Initiated
Berenberg
Buy
$27
Jan-05-23 Initiated
Scotiabank
Sector Outperform
$33
Jan-03-23 Upgrade
Evercore ISI
In-line → Outperform
$28 → $36
Mar-02-22 Resumed
Cowen
Outperform
Oct-15-21 Resumed
Cowen
Outperform
Jun-29-21 Initiated
William Blair
Outperform
Jun-04-21 Initiated
Goldman
Neutral
$110
Apr-12-21 Initiated
Piper Sandler
Overweight
$150
Feb-05-21 Downgrade
JP Morgan
Neutral → Underweight
$100
Jan-04-21 Downgrade
Evercore ISI
Outperform → In-line
Oct-20-20 Initiated
SVB Leerink
Mkt Perform
$90
May-31-19 Initiated
Evercore ISI
Outperform
Nov-26-18 Initiated
JP Morgan
Neutral
$27
Show Previous Ratings
May-24-24 04:58PM
(Investor's Business Daily)
May-23-24 08:00AM
May-22-24 12:00PM
May-13-24 08:00AM
May-10-24 06:00AM
08:00AM
Loading…
May-08-24 08:00AM
May-03-24 03:55PM
01:58PM
01:22PM
10:02AM
06:47AM
(Thomson Reuters StreetEvents)
04:05AM
May-02-24 09:00PM
05:35PM
04:33PM
(Associated Press Finance)
04:05PM
Loading…
04:05PM
Apr-30-24 03:20PM
Apr-25-24 11:31AM
Apr-18-24 08:00AM
Mar-28-24 08:00AM
Mar-05-24 08:00AM
Feb-22-24 08:00AM
Feb-13-24 01:59PM
Feb-10-24 05:28AM
Feb-07-24 08:00AM
Feb-06-24 08:05AM
08:00AM
Feb-05-24 08:09AM
08:00AM
Feb-02-24 11:42PM
(Thomson Reuters StreetEvents) +10.01%
07:55AM
Loading…
07:55AM
07:36AM
(Associated Press Finance)
07:30AM
Jan-24-24 08:00AM
Jan-16-24 08:00AM
Jan-08-24 08:00AM
Jan-05-24 08:00AM
Dec-19-23 12:44PM
Dec-18-23 08:00AM
Dec-15-23 08:11AM
Nov-20-23 08:55AM
Nov-18-23 01:29AM
(Thomson Reuters StreetEvents)
Nov-17-23 04:03PM
(Investor's Business Daily) +25.90%
08:40AM
08:28AM
07:47AM
(Associated Press Finance)
07:30AM
Nov-14-23 08:00AM
Nov-13-23 08:00AM
Nov-08-23 08:00AM
Nov-02-23 04:05PM
Oct-31-23 08:00AM
Oct-16-23 10:43AM
Oct-06-23 12:08PM
11:44AM
Oct-05-23 08:00AM
Oct-03-23 08:00AM
Sep-27-23 08:00AM
Sep-26-23 01:02PM
12:40PM
Sep-20-23 12:11PM
Sep-14-23 12:56PM
12:31PM
Sep-05-23 08:00AM
Aug-31-23 03:10AM
03:00AM
Aug-22-23 08:00AM
Aug-11-23 01:39PM
Aug-07-23 09:53AM
08:00AM
Aug-04-23 01:21PM
08:45AM
07:37AM
07:30AM
Jul-20-23 08:00AM
Jul-18-23 09:50AM
08:00AM
Jun-26-23 08:10AM
Jun-20-23 08:00AM
Jun-04-23 09:46AM
May-31-23 08:00AM
May-24-23 08:00AM
May-23-23 08:00AM
May-22-23 08:00AM
May-14-23 04:05PM
May-10-23 08:00AM
May-08-23 08:54AM
May-07-23 01:18PM
May-05-23 11:02AM
08:45AM
07:30AM
May-03-23 08:45AM
May-02-23 05:53AM
Apr-28-23 10:00AM
Apr-27-23 08:00AM
Apr-26-23 02:10PM
Apr-25-23 10:00AM
06:35AM
Apr-20-23 06:24PM
08:00AM
Twist Bioscience Corp. engages in the development of a proprietary semiconductor-based synthetic DNA manufacturing process. It operates through the following geographical segments: Americas, EMEA, and APAC. The Americas segment consists of the United States of America, Canada, Mexico, and South America. The EMEA segment includes Europe, Middle East, and Africa. The APAC segment focuses on Japan, China, South Korea, India, Singapore, Malaysia, and Australia. The company was founded by William Marine Banyai, Emily Marine Leproust, and Bill James Peck on February 4, 2013 and is headquartered in San Francisco, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Leproust Emily M. Chief Executive Officer May 03 '24 Sale 37.13 4,163 154,589 509,986 May 07 04:05 PM Finn Patrick John President and COO May 03 '24 Sale 37.13 2,311 85,817 173,895 May 07 04:05 PM Green Paula SVP of Human Resources May 03 '24 Sale 37.13 910 33,792 91,511 May 07 04:05 PM Banyai William See Remark May 03 '24 Sale 37.13 798 29,633 345,188 May 07 04:05 PM Cho Dennis See Remarks May 03 '24 Sale 37.13 568 21,092 80,436 May 07 04:05 PM WERNER ROBERT F. Chief Accounting Officer May 03 '24 Sale 37.13 132 4,902 43,548 May 07 04:05 PM Finn Patrick John President and COO Apr 23 '24 Sale 30.12 2,174 65,483 176,206 Apr 25 04:05 PM Laponis Adam Chief Financial Officer Apr 09 '24 Sale 33.16 556 18,434 74,444 Apr 11 04:05 PM Leproust Emily M. Chief Executive Officer Apr 02 '24 Sale 32.74 1,132 37,057 514,149 Apr 04 04:05 PM Finn Patrick John President and COO Apr 02 '24 Sale 32.74 492 16,106 178,380 Apr 04 04:05 PM Banyai William See Remark Apr 02 '24 Sale 32.74 327 10,705 345,986 Apr 04 04:05 PM Green Paula SVP of Human Resources Apr 02 '24 Sale 32.74 229 7,497 92,421 Apr 04 04:05 PM Cho Dennis See Remarks Apr 02 '24 Sale 32.74 129 4,223 81,004 Apr 04 04:05 PM Leproust Emily M. Chief Executive Officer Mar 20 '24 Sale 33.52 1,128 37,806 515,281 Mar 22 04:05 PM Banyai William See Remark Mar 20 '24 Sale 33.52 442 14,814 346,313 Mar 22 04:05 PM Cho Dennis See Remarks Mar 20 '24 Sale 33.52 230 7,709 81,133 Mar 22 04:05 PM Green Paula SVP of Human Resources Mar 20 '24 Sale 33.52 200 6,703 92,650 Mar 22 04:05 PM Cho Dennis See Remarks Mar 14 '24 Sale 34.60 93 3,218 81,363 Mar 18 04:05 PM Leproust Emily M. Chief Executive Officer Mar 06 '24 Sale 37.43 1,487 55,658 516,409 Mar 08 04:05 PM Green Paula SVP of Human Resources Mar 06 '24 Sale 37.43 600 22,458 92,850 Mar 08 04:05 PM Banyai William See Remark Mar 06 '24 Sale 37.43 549 20,549 346,755 Mar 08 04:05 PM Cho Dennis See Remarks Mar 06 '24 Sale 37.43 272 10,181 81,456 Mar 08 04:05 PM WERNER ROBERT F. Chief Accounting Officer Mar 06 '24 Sale 37.43 181 6,775 43,680 Mar 08 04:05 PM CHESS ROBERT Director Feb 08 '24 Sale 34.98 4,110 143,784 64,169 Feb 09 04:10 PM
Index RUT
P/E -
EPS (ttm) -1.07
Insider Own 27.71%
Shs Outstand 32.52M
Perf Week -5.11%
Market Cap 224.19M
Forward P/E -
EPS next Y -0.96
Insider Trans -0.16%
Shs Float 24.93M
Perf Month 14.64%
Income -34.78M
PEG -
EPS next Q -0.33
Inst Own 56.29%
Short Float 4.20%
Perf Quarter -13.56%
Sales 50.73M
P/S 4.42
EPS this Y 1.42%
Inst Trans 3.34%
Short Ratio 4.66
Perf Half Y -7.54%
Book/sh 4.77
P/B 1.36
EPS next Y 13.64%
ROA -17.04%
Short Interest 1.05M
Perf Year -30.33%
Cash/sh 3.89
P/C 1.67
EPS next 5Y -
ROE -20.61%
52W Range 4.85 - 12.51
Perf YTD -42.07%
Dividend Est. -
P/FCF -
EPS past 5Y -31.19%
ROI -21.70%
52W High -48.04%
Beta 1.07
Dividend TTM -
Quick Ratio 7.53
Sales past 5Y 21.26%
Gross Margin 46.13%
52W Low 34.02%
ATR (14) 0.38
Dividend Ex-Date -
Current Ratio 8.37
EPS Y/Y TTM 7.26%
Oper. Margin -83.26%
RSI (14) 53.08
Volatility 5.39% 6.19%
Employees 230
Debt/Eq 0.03
Sales Y/Y TTM 5.62%
Profit Margin -68.56%
Recom 1.00
Target Price 15.33
Option/Short Yes / Yes
LT Debt/Eq 0.02
EPS Q/Q 14.87%
Payout -
Rel Volume 0.41
Prev Close 6.48
Sales Surprise 7.52%
EPS Surprise 8.84%
Sales Q/Q 5.31%
Earnings Apr 30 BMO
Avg Volume 224.32K
Price 6.50
SMA20 4.20%
SMA50 3.19%
SMA200 -5.29%
Trades
Volume 36,511
Change 0.31%
Date
Action
Analyst
Rating Change
Price Target Change
Feb-07-23 Initiated
Stephens
Overweight
$14
Oct-15-21 Resumed
Cowen
Outperform
Jan-12-21 Initiated
William Blair
Outperform
Jan-12-21 Initiated
SVB Leerink
Outperform
$70
Jan-12-21 Initiated
Stifel
Buy
$65
Jan-12-21 Initiated
Cowen
Outperform
May-15-24 07:00AM
May-14-24 09:55AM
May-09-24 09:35AM
May-01-24 08:49AM
03:09AM
12:08AM
Loading…
12:08AM
(Thomson Reuters StreetEvents)
Apr-30-24 11:53AM
09:35AM
08:55AM
07:45AM
07:30AM
Apr-23-24 07:00AM
Mar-12-24 07:00AM
Mar-07-24 12:02PM
Mar-05-24 07:33AM
07:00AM
Loading…
07:00AM
Feb-29-24 07:00AM
Feb-22-24 07:00AM
Feb-20-24 07:00AM
Feb-02-24 11:01PM
Dec-28-23 12:00PM
Dec-27-23 10:30AM
Dec-22-23 01:01PM
Dec-19-23 09:55AM
Dec-18-23 05:34AM
Nov-14-23 07:00AM
Nov-09-23 03:37PM
Nov-07-23 08:14AM
07:00AM
Nov-06-23 04:30PM
07:00AM
Loading…
Oct-31-23 07:00AM
Oct-24-23 04:30PM
07:00AM
Sep-26-23 07:00AM
Sep-18-23 07:00AM
Sep-15-23 07:00AM
Aug-26-23 07:50AM
Aug-08-23 09:15AM
07:00AM
Aug-07-23 07:00AM
Jul-31-23 07:00AM
Jul-25-23 07:00AM
Jul-16-23 08:42AM
Jul-13-23 05:42AM
May-30-23 07:00AM
May-23-23 09:54AM
07:00AM
May-09-23 08:25AM
07:00AM
May-04-23 07:00AM
Apr-26-23 07:00AM
Apr-25-23 07:00AM
Apr-18-23 11:14AM
Mar-08-23 02:22AM
(Thomson Reuters StreetEvents)
Mar-07-23 08:25AM
07:00AM
Feb-27-23 06:05PM
Feb-21-23 07:00AM
Feb-14-23 07:00AM
Feb-07-23 01:37PM
Feb-06-23 05:16AM
Jan-17-23 07:00AM
Dec-29-22 06:02AM
Dec-07-22 07:00AM
Nov-16-22 06:24AM
Nov-14-22 11:44AM
10:05AM
07:00AM
Nov-10-22 07:00AM
Nov-09-22 07:00AM
Nov-02-22 07:00AM
Oct-19-22 07:00AM
Oct-12-22 05:00PM
Sep-29-22 07:50AM
Aug-09-22 04:00PM
08:45AM
07:30AM
07:00AM
Jul-27-22 07:00AM
Jul-25-22 07:21AM
Jul-19-22 07:00AM
Jun-13-22 04:22PM
Jun-02-22 07:00AM
May-26-22 07:00AM
May-11-22 02:30AM
May-10-22 08:15AM
07:00AM
May-09-22 07:00AM
May-03-22 07:00AM
Apr-21-22 07:00AM
Apr-12-22 05:37PM
07:00AM
Mar-08-22 05:58PM
Mar-07-22 10:30PM
05:15PM
04:05PM
Mar-02-22 04:30PM
Feb-15-22 07:00AM
Feb-14-22 12:24PM
Feb-08-22 07:00AM
908 Devices, Inc. engages in the development of measurement devices for chemical and biochemical analysis. It offers products using mass spectrometry technology, an analytical technique for measuring the mass of charged molecules that is used in chemical analysis laboratories for applications, such as safety and security, food science, biotechnology, clinical diagnostics, and controlling industrial processes. Its products include desktops and handhelds. The company was founded by Kevin J. Knopp, Miller Scott, Steve Araiza, Andrew Bartfay, Michael Jobin, Christopher D. Brown, and Christopher J. Petty in 2012 and is headquartered in Boston, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Knopp Kevin J. President and CEO May 13 '24 Buy 6.42 10,000 64,200 508,981 May 13 04:42 PM Knopp Kevin J. President and CEO May 10 '24 Buy 5.77 10,000 57,700 498,981 May 10 06:36 PM Knopp Kevin J. President and CEO May 09 '24 Buy 5.83 10,000 58,300 488,981 May 09 04:34 PM Knopp Kevin J. President and CEO May 08 '24 Buy 5.72 10,000 57,200 478,981 May 08 09:31 PM Knopp Kevin J. President and CEO May 07 '24 Buy 5.60 10,000 56,000 468,981 May 07 06:07 PM Knopp Kevin J. President and CEO Apr 16 '24 Option Exercise 1.75 47,000 82,250 458,981 Apr 16 04:11 PM Brown Christopher D. Chief Product Officer Apr 01 '24 Option Exercise 1.75 3,600 6,300 884,994 Apr 02 04:06 PM Griffith Joseph H. IV Chief Financial Officer Mar 26 '24 Option Exercise 1.58 8,437 13,330 93,437 Mar 27 04:16 PM Griffith Joseph H. IV Chief Financial Officer Feb 02 '24 Sale 7.09 9,711 68,873 80,000 Feb 02 07:10 PM Knopp Kevin J. President and CEO Feb 01 '24 Sale 7.00 9,071 63,461 411,981 Feb 02 04:39 PM Griffith Joseph H. IV Chief Financial Officer Feb 01 '24 Sale 7.00 5,698 39,892 89,711 Feb 02 07:10 PM Turner Michael S. Chief Legal & Admin Officer Feb 01 '24 Sale 6.99 5,232 36,559 9,105 Feb 02 04:40 PM Brown Christopher D. Chief Product Officer Feb 01 '24 Sale 7.01 3,957 27,730 886,394 Feb 02 04:37 PM Griffith Joseph H. IV Chief Financial Officer Dec 28 '23 Sale 12.08 6,000 72,480 80,000 Jan 02 05:01 PM Brown Christopher D. Chief Product Officer Dec 21 '23 Sale 9.12 7,370 67,214 877,905 Dec 21 04:46 PM Brown Christopher D. Chief Product Officer Dec 20 '23 Sale 9.10 5,235 47,638 885,275 Dec 21 04:46 PM Brown Christopher D. Chief Product Officer Dec 19 '23 Sale 9.08 7,395 67,147 890,510 Dec 21 04:46 PM Griffith Joseph H. IV Chief Financial Officer Dec 19 '23 Sale 9.08 5,580 50,666 86,000 Dec 21 04:47 PM Brown Christopher D. Chief Product Officer Jun 07 '23 Sale 10.03 4,470 44,834 897,905 Jun 09 04:17 PM Knopp Kevin J. President and CEO Jun 05 '23 Option Exercise 1.75 28,500 49,875 396,348 Jun 05 04:07 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite